Scientia Vascular develops advanced access products designed to improve simplicity and precision during neurovascular interventions.
In addition, the investment will strengthen research into emerging treatment areas such as heart failure and renal denervation, a minimally invasive therapy for uncontrolled hypertension.
The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.